• An investigation into Takara Holdings subsidiary Takara Bio USA found no intentional improper accounting or material impact on consolidated financial statements.
• Only quantitatively immaterial errors were identified; no corrections to prior-year consolidated financial statements are required.
• The auditor issued an unmodified interim review conclusion on October 23, 2026, for first-quarter financial statements for the fiscal year ending March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takara Holdings Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.